Status: Recruiting
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.
Participants needed: 510
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Immuneering CorporationUpdated: Jun 22, 2026Locations: 19
Eligibility criteria
Must be ≥18 years of age [+5]
Inability to swallow oral medications [+3]